Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ \[height (m)\]²~* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized and men, ages 18 to 45~Exclusion Criteria:~* WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period~* Any significant acute or chronic medical illness~* Current or recent (within 3 months) gastrointestinal disease~* Current smoker or recent (within 1 month) history of regular tobacco use~* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population~* Abnormal urinalysis at screening~* Glucosuria at screening~* Abnormal liver functions tests (ALT, AST or total bilirubin \> 10 % ULN)~* Presence of edema on physical exam~* History of diabetes mellitus~* History of heart failure~* History of renal insufficiency~* History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months~* Positive urine screen for drugs of abuse either at screening or before dosing~* Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody~* History of allergy to SGLT2 inhibitors, bumetanide (or related compounds)~* History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)~* Prior exposure to dapagliflozin within 3 months of Day -1~* Exposure to any investigational drug or placebo within 4 weeks of Day -1~* Use of any prescription drugs within 4 weeks or over-the-counter acid controllers within 2 weeks prior to study drug administration~* Use of any other drugs, including over-the-counter medications within 1 week and herbal preparations, within 2 weeks prior to study drug administration~* Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months of study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Bumetanide (Type: ACTIVE_COMPARATOR): None
- Dapagliflozin (Type: ACTIVE_COMPARATOR): None
- Bumetanide + Dapagliflozin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).